Published in Ann N Y Acad Sci on October 01, 2010
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Deterministic separation of cancer cells from blood at 10 mL/min. AIP Adv (2012) 1.30
Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl (2013) 1.21
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One (2014) 1.14
Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates. Adv Mater (2013) 1.13
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 1.07
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A (2013) 1.02
Expression of E-selectin ligands on circulating tumor cells: cross-regulation with cancer stem cell regulatory pathways? Front Oncol (2012) 0.93
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices. Biomed Microdevices (2012) 0.91
Monitoring the progression of metastatic breast cancer on nanoporous silica chips. Philos Trans A Math Phys Eng Sci (2012) 0.90
Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS One (2012) 0.89
Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res (2011) 0.87
Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr (2012) 0.84
Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer. J Breast Cancer (2012) 0.82
Photoacoustic imaging: a potential tool to detect early indicators of metastasis. Expert Rev Med Devices (2013) 0.80
Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. Theranostics (2016) 0.78
Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.78
CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. Transl Lung Cancer Res (2013) 0.75
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. Cell Death Discov (2017) 0.75
Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. Oncotarget (2016) 0.75
Circulating tumor cell detection in hepatocellular carcinoma based on karyoplasmic ratios using imaging flow cytometry. Sci Rep (2016) 0.75
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74
Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res (2008) 2.06
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 1.79
Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71
Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res (2012) 1.63
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst (2005) 1.60
Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res (2011) 1.58
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56
Biologic challenges in the detection of circulating tumor cells. Cancer Res (2012) 1.55
Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2012) 1.53
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res (2003) 1.53
Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res (2006) 1.52
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50
Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther (2007) 1.50
Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev (2012) 1.47
Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology (2008) 1.47
Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res (2004) 1.40
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res (2004) 1.33
Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res (2004) 1.31
Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res (2012) 1.30
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29
Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem (2007) 1.28
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25
High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer (2003) 1.25
Technologies for detection of circulating tumor cells: facts and vision. Lab Chip (2013) 1.24
Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer (2013) 1.23
Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother (2013) 1.23
Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int (2010) 1.22
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol (2011) 1.21
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 1.21
Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood (2013) 1.19
Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res (2009) 1.19
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci (2008) 1.17
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol (2012) 1.16
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat (2012) 1.16
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods (2005) 1.13
Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res (2009) 1.12
Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol (2003) 1.11
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat (2012) 1.11
L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol (2007) 1.10
Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem (2013) 1.10
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat (2010) 1.09
Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem (2013) 1.09
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res (2008) 1.09
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat (2014) 1.08
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal (2011) 1.08
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer (2003) 1.08
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol (2008) 1.07
Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem (2013) 1.07
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res (2009) 1.06
Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One (2012) 1.06
Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res (2007) 1.05
Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res (2003) 1.05
Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer (2008) 1.04
Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res (2006) 1.03
Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance. Eur J Cardiothorac Surg (2003) 1.03
Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile. J Proteome Res (2009) 1.02
High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer (2011) 1.02
Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer (2011) 1.02
Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res (2012) 1.01
The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. J Pathol (2012) 1.00
Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int (2006) 1.00
Molecular mechanisms of metastasis. Cancer Metastasis Rev (2006) 1.00
Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer (2003) 0.99